For carriers of STK11 PGV, risk is reported as: (i) an absolute risk of BC ranging from 32 to 54% and (ii) an absolute risk of nonepithelial ovarian cancer (Sertoli-Leydig) from 10 to 20% [4,12]. Here, STK11 is linked to breast cancer.